EDITORIAL
Revisiting the copd mega-trials in the new decade: The end of the road or just a new beginning?
 
More details
Hide details
1
Editorial Board Pneumon
CORRESPONDING AUTHOR
Stelios Loukides   

Smolika 2 16673 Athens
 
Pneumon 2011;24(1):27–29
 
 
REFERENCES (19)
1.
Rabe KF, Hurd S, Anzueto A, et al. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-55.
 
2.
Tashkin DP, Celli B, Senn S, et al; UPLIFT Study Investigators. Α 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543-54.
 
3.
Calverley PM, Anderson JA, Celli B, et al. TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89.
 
4.
Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP. UPLIFT investigators. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009;374:1171-8.
 
5.
Troosters T, Celli B, Lystig T, et al. Uplift Investigators. Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial. Eur Respir J 2010;36:65-73.
 
6.
Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008;178:332-8.
 
7.
enkins CR, Jones PW, Calverley PM, et al. Efficacy of salmeterol/ fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebocontrolled TORCH study. Respir Res 2009;10:59.
 
8.
Morice AH, Celli B, Kesten S, Lystig T, Tashkin D, Decramer M. COPD in young patients: a pre-specified analysis of the fouryear trial of tiotropium (UPLIFT). Respir Med 2010;104:1659-67.
 
9.
Welte T, Miravitlles M, Hernandez P, et al. Efficacy and Tolerability of Budesonide/Formoterol Added to Tiotropium in Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2009;180:741-50.
 
10.
Aaron SD, Vandemheen KL, Fergusson D, et al; Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007;146:545-55.
 
11.
Dahl R, Chung KF, Buhl R, et al; INVOLVE (INdacaterol: Value in COPD: Longer Term Validation of Efficacy and Safety) Study Investigators. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax 2010;65:473-9.
 
12.
Donohue JF, Fogarty C, Lötvall J, et al; INHANCE Study Investigators. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010;182:155-62.
 
13.
Rabe KF. Roflumilast for the treatment of chronic obstructive pulmonary disease. Expert Rev Respir Med 2010;4:543-55.
 
14.
Kostikas K, Bakakos P, Loukides S. Phosphodiesterase 4 inhibitors: A new treatment option for copd. Are we there yet? Pneumon 2009;4:290-5.
 
15.
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2010. Available from: http://www.goldcopd.com.
 
16.
Kostikas K, Bouros D. ”Show me the money”: a fair criticism of economic studies on inhaled bronchodilators in COPD. BMC Pulm Med 2010;10:48.
 
17.
Decramer M, Cooper CB. Treatment of COPD: the sooner the better? Thorax 2010;65:837-41.
 
18.
Vestbo J, Anderson JA, Calverley PM, et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax 2009;64:939-43.
 
19.
Bakakos P, Kostikas K, Loukides S. COPD and co-morbidities. Pneumon 2010;1:21-7.
 
eISSN:1791-4914
ISSN:1105-848X